In HCT116 colon cancer cells that we had previously genetically manipulated to express various mutant active H-RAS proteins we discovered that loss of mutant active K-RAS D13 signaling enhanced the lethality of [pemetrexed + sorafenib] but did not further enhance killing by the three drug combination. This evidence concerns the gene HRAS and colonic neoplasm.